Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

VALSARTAN; HYDROCHLOROTHIAZIDE (VALSARTAN; HYDROCHLOROTHIAZIDE) | LOERadar

Viewing data from:

Tentative Approval — This application has been tentatively approved by the FDA but is not yet listed in the Orange Book. It is blocked from final approval by unexpired patents or exclusivities on the reference listed drug.

VALSARTAN; HYDROCHLOROTHIAZIDE

ANDA

Tentative Approval

VALSARTAN; HYDROCHLOROTHIAZIDE | A091654 | TORRENT PHARMS LTD

Products (5)

Sort:

#001 — 80MG; 12.5MG

▴

TABLET; ORAL | TA Date: 2012-04-10 00:00:00

No patent or exclusivity listings for this strength.

#002 — 160MG; 12.5MG

▾

TABLET; ORAL | TA Date: 2012-04-10 00:00:00

#003 — 160MG; 25MG

▾

TABLET; ORAL | TA Date: 2012-04-10 00:00:00

#004 — 320MG; 12.5MG

▾

TABLET; ORAL | TA Date: 2012-04-10 00:00:00

#005 — 320MG; 25MG

▾

TABLET; ORAL | TA Date: 2012-04-10 00:00:00